Humacyte Historical Income Statement

HUMAW Stock

USD 2.16 0.31 16.76%

Historical analysis of Humacyte income statement accounts such as Selling General Administrative of 21.1 M or Total Revenue of 0.0 can show how well Humacyte performed in making a profits. Evaluating Humacyte income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Humacyte's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Humacyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Humacyte is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

About Humacyte Income Statement Analysis

Humacyte Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Humacyte shareholders. The income statement also shows Humacyte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Humacyte Income Statement Chart

At this time, Humacyte's Depreciation And Amortization is fairly stable compared to the past year. Cost Of Revenue is likely to climb to about 80.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.1 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Cost Of Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Humacyte. It is also known as Humacyte overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Humacyte income statement and represents the costs associated with goods and services Humacyte provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Humacyte's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.At this time, Humacyte's Depreciation And Amortization is fairly stable compared to the past year. Cost Of Revenue is likely to climb to about 80.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	4.3M	6.2M	1.1M	1.1M
Depreciation And Amortization	8.3M	8.3M	7.7M	8.7M

Interest Expense Depreciation And Amortization

Humacyte income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Net Interest Income	Interest Income	Net Income From Continuing Ops	Reconciled Depreciation	Income Tax Expense	Selling And Marketing Expenses
Depreciation And Amortization		0.27	0.5	-0.95	0.68	-0.53	-0.04	0.27	-0.76	0.3	-0.69	0.76	0.35	0.42	0.48	-0.21	0.59	0.28	-0.6	-0.52	-0.55
Interest Expense	0.27		0.33	-0.15	0.74	-0.36	0.36	0.88	-0.52	0.89	-0.73	0.77	0.96	0.97	0.96	-0.89	-0.22	0.99	0.3	-0.93	0.44
Selling General Administrative	0.5	0.33		-0.65	0.16	0.36	-0.66	0.13	-0.01	0.15	-0.19	0.36	0.21	0.48	0.43	-0.18	0.73	0.28	-0.47	-0.58	-0.53
Total Revenue	-0.95	-0.15	-0.65		-0.53	0.32	0.22	-0.14	0.6	-0.16	0.56	-0.65	-0.2	-0.32	-0.36	0.07	-0.75	-0.14	0.6	0.45	0.64
Gross Profit	0.68	0.74	0.16	-0.53		-0.82	0.59	0.68	-0.95	0.7	-1.0	0.98	0.87	0.78	0.85	-0.78	-0.12	0.78	0.12	-0.8	0.24
Other Operating Expenses	-0.53	-0.36	0.36	0.32	-0.82		-0.81	-0.47	0.93	-0.49	0.81	-0.71	-0.56	-0.34	-0.45	0.45	0.3	-0.42	-0.16	0.33	-0.28
Operating Income	-0.04	0.36	-0.66	0.22	0.59	-0.81		0.47	-0.62	0.46	-0.57	0.42	0.54	0.24	0.32	-0.48	-0.75	0.41	0.68	-0.16	0.76
Ebit	0.27	0.88	0.13	-0.14	0.68	-0.47	0.47		-0.56	1.0	-0.68	0.7	0.84	0.79	0.79	-0.64	-0.16	0.82	0.32	-0.72	0.43
Research Development	-0.76	-0.52	-0.01	0.6	-0.95	0.93	-0.62	-0.56		-0.58	0.94	-0.9	-0.68	-0.56	-0.65	0.55	0.04	-0.56	0.0	0.58	-0.1
Ebitda	0.3	0.89	0.15	-0.16	0.7	-0.49	0.46	1.0	-0.58		-0.69	0.72	0.84	0.79	0.8	-0.64	-0.15	0.83	0.3	-0.73	0.42
Cost Of Revenue	-0.69	-0.73	-0.19	0.56	-1.0	0.81	-0.57	-0.68	0.94	-0.69		-0.98	-0.86	-0.78	-0.85	0.76	0.09	-0.77	-0.13	0.8	-0.22
Total Operating Expenses	0.76	0.77	0.36	-0.65	0.98	-0.71	0.42	0.7	-0.9	0.72	-0.98		0.86	0.84	0.89	-0.75	0.06	0.79	0.01	-0.87	0.1
Income Before Tax	0.35	0.96	0.21	-0.2	0.87	-0.56	0.54	0.84	-0.68	0.84	-0.86	0.86		0.95	0.97	-0.95	-0.32	0.98	0.36	-0.91	0.5
Total Other Income Expense Net	0.42	0.97	0.48	-0.32	0.78	-0.34	0.24	0.79	-0.56	0.79	-0.78	0.84	0.95		0.99	-0.91	-0.08	0.97	0.15	-0.99	0.29
Net Income	0.48	0.96	0.43	-0.36	0.85	-0.45	0.32	0.79	-0.65	0.8	-0.85	0.89	0.97	0.99		-0.92	-0.11	0.97	0.15	-0.98	0.29
Net Interest Income	-0.21	-0.89	-0.18	0.07	-0.78	0.45	-0.48	-0.64	0.55	-0.64	0.76	-0.75	-0.95	-0.91	-0.92		0.44	-0.95	-0.38	0.87	-0.54
Interest Income	0.59	-0.22	0.73	-0.75	-0.12	0.3	-0.75	-0.16	0.04	-0.15	0.09	0.06	-0.32	-0.08	-0.11	0.44		-0.29	-0.8	-0.04	-0.91
Net Income From Continuing Ops	0.28	0.99	0.28	-0.14	0.78	-0.42	0.41	0.82	-0.56	0.83	-0.77	0.79	0.98	0.97	0.97	-0.95	-0.29		0.3	-0.93	0.46
Reconciled Depreciation	-0.6	0.3	-0.47	0.6	0.12	-0.16	0.68	0.32	0.0	0.3	-0.13	0.01	0.36	0.15	0.15	-0.38	-0.8	0.3		-0.04	0.95
Income Tax Expense	-0.52	-0.93	-0.58	0.45	-0.8	0.33	-0.16	-0.72	0.58	-0.73	0.8	-0.87	-0.91	-0.99	-0.98	0.87	-0.04	-0.93	-0.04		-0.16
Selling And Marketing Expenses	-0.55	0.44	-0.53	0.64	0.24	-0.28	0.76	0.43	-0.1	0.42	-0.22	0.1	0.5	0.29	0.29	-0.54	-0.91	0.46	0.95	-0.16

Click cells to compare fundamentals

Humacyte Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Humacyte Historical Income Statement

About Humacyte Income Statement Analysis

Humacyte Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Humacyte income statement Correlations

Humacyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Humacyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income From Continuing Ops	+ 0.99	Interest Expense
Net Income	+ 0.99	Total Other Income Expense Net
Total Operating Expenses	+ 0.98	Gross Profit
Net Income From Continuing Ops	+ 0.98	Income Before Tax
Total Other Income Expense Net	+ 0.97	Interest Expense

Cost Of Revenue	- 1.0	Gross Profit
Income Tax Expense	- 0.99	Total Other Income Expense Net
Income Tax Expense	- 0.98	Net Income
Total Operating Expenses	- 0.98	Cost Of Revenue
Net Income From Continuing Ops	- 0.95	Net Interest Income
Net Interest Income	- 0.95	Income Before Tax